Slingshot AI vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Slingshot AI raised $93M (a16z) for its Ash therapy chatbot with 50K beta users; withdrew from UK over medical device concerns while expanding US CBT-informed AI mental health access.
About
Slingshot AI is a mental health technology company developing AI-powered therapy and emotional support tools designed to expand access to mental health care. Backed by Andreessen Horowitz (a16z), Slingshot has built Ash, a conversational AI therapy chatbot that provides CBT-informed and evidence-based support to users between professional therapy sessions or as a standalone resource for people who cannot access or afford traditional therapy. The company was founded on the premise that the global mental health crisis — characterized by a severe shortage of therapists relative to need — requires AI-enabled solutions to close the access gap.\n\nAsh is designed to conduct structured therapeutic conversations, guide users through mental health exercises, track mood and symptom patterns over time, and provide crisis resources when needed. The platform is built with clinical input and aims to function at the boundary between a mental wellness app and a clinical-grade tool, offering more depth than meditation apps while being accessible without a prescription or insurance. Slingshot has enrolled 50,000+ beta users who have engaged with Ash's conversational therapy features across depression, anxiety, and stress-related concerns.\n\nSlingshot has raised $93M in total funding, backed by a16z and other investors, reflecting strong venture conviction in the mental health AI space despite a complex regulatory environment. The company made a notable decision to withdraw from the UK market in January 2026 over concerns about medical device regulatory requirements — the UK's MHRA was signaling that AI therapy tools would require medical device classification, raising the compliance burden significantly. This withdrawal highlights the tension between the consumer mental health app model and the regulatory frameworks emerging around AI clinical tools, a challenge Slingshot and the broader mental health AI category are actively navigating.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.